Inhaled Interferon for Asthma Treatment (NR): A narrative review
1 Family Medicine Department, Al Jazeerah Health Center, Emirates Health Service – Ministry of Health and Prevention, Ras Al Khaimah, United Arab Emirates.
2 Family Medicine Department, Abdullah bin Ali Al Sharhan Health Center, Emirates Health Service – Ministry of Health and Prevention, Ras Al Khaimah, United Arab Emirates.
3 Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
Review
World Journal of Biology Pharmacy and Health Sciences, 2024, 19(01), 290–297.
Article DOI: 10.30574/wjbphs.2024.19.1.0437
Publication history:
Received on 10 June 2024; revised on 20 July 2024; accepted on 22 July 2024
Abstract:
Although various therapeutic strategies, such as inhalant beta-2 agonists, corticosteroids, anti-leukotrienes, and even novel inclusion of active biological agents in the management of asthma have been established, as asthma is a global issue and chronic in nature, the search for potential new tools to the arsenal continues to this day. Remarkable progress has recently been achieved in identifying the pathophysiology and potential value of interferons (IFNs) in managing allergic asthma. This narrative review attempts to precisely demonstrate the possible use of inhalant IFNs in differing asthmatic conditions by simplifying and concluding studies published between 1995 and 2021. Review findings indicate that IFN lambda and gamma could be utilized as primary tools in asthma management, while IFN beta can be used as an adjuvant therapy for viral-induced severe asthmatic exacerbations.
Keywords:
Inhaled interferons; Asthma management; Asthma exacerbation; Interferon gamma; Interferon beta; Interferon lambda
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0